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SUMMARY
MyD88, the intracellular adaptor of most TLRs, mediates either pro-inflammatory or
immunosuppressive signaling that contributes to chronic inflammation-associated diseases.
Although gene-specific chromatin modifications regulate inflammation, the role of MyD88
signaling in establishing such epigenetic landscapes under different inflammatory states remains
elusive. Using quantitative proteomics to enumerate the inflammation-phenotypic constituents of
MyD88 interactome, we found that in endotoxin-tolerant macrophages PP2Ac enhances its
association with MyD88, and is constitutively activated. Knockdown of PP2Ac prevents
suppression of pro-inflammatory genes and resistance to apoptosis. Through sitespecific
dephosphorylation constitutively active PP2Ac disrupts the signal-promoting TLR4-MyD88
complex, and broadly suppresses the activities of multiple pro-inflammatory/proapoptotic
pathways as well, shifting pro-inflammatory MyD88 signaling to a pro-survival mode.
Constitutively active PP2Ac translocated with MyD88 into the nuclei of tolerant macrophages
establishes the immunosuppressive pattern of chromatin modifications and represses chromatin
remodeling to selectively silence pro-inflammatory genes, coordinating the MyD88-dependent
inflammation control at both signaling and epigenetic levels under endotoxin-tolerant conditions.
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Toll-like receptors (TLRs) activate the innate immune system by mounting appropriate
inflammatory responses to contain infection or repair damaged tissues(Drexler and
Foxwell). To avoid harmful effects of persistent signaling caused by the continual presence
of stimuli, cells become transiently unresponsive by acquiring tolerance to chronic
inflammation, leading to a negative consequence that tumor cells can escape
immunosurveillance(Rakoff-Nahoum and Medzhitov, 2009). In transmitting inflammatory
signals, by mechanisms yet to be elucidated, the intracellular adaptor protein MyD88 of
most TLRs acts as a double-edged sword promoting both protective and harmful
inflammation(Huang et al., 2008).
Recent work has revealed that inflammation control is achieved by a gene-specific
mechanism in which distinct chromatin modifications contribute to selective silencing of
TLR4-induced pro-inflammatory or tolerizable (T-class) genes under an endotoxin tolerance
(ET)-associated chronic inflammatory state (Foster et al., 2007). Major questions remain
unanswered including (1) how does MyD88 mediate both acute and chronic inflammatory
responses? (2) What is the driving force for ‘converting’ pro-inflammatory MyD88 to an
immunosuppressive mediator? (3) How are distinct, inflammation-specific patterns of
chromatin modifications differentially established at the T-class promoters?
Emerging evidence suggests that an effective, unharmful inflammatory response is
intrinsically regulated by subtly distinct intracellular protein interactions, i.e.,
‘interactomes,’ involved in signal transduction(Liew et al., 2005). During TLR signaling,
MyD88 serves as a scaffold that coordinates protein complex assembly through sequential
recruitment of specific proteins varying from TLR molecules to downstream proteins(Dai et
al., 2009; Wang et al., 2006). Based on our previous identification of multiple, novel signal
regulators that interact with MyD88 in a timely and orderly manner to tightly regulate the
amplitude and duration of TLR signaling(Dai et al., 2009), we reason that MyD88 may
regulate either acute or chronic inflammation via assembling different, inflammation-
phenotypic interactomes.
RESULTS
As a Core Component of MyD88 Interactome in ET Macrophages PP2Ac is Chronically
Activated
First, by using our AACT-based quantitative proteomic approach(Chen et al., 2000) with
modifications for interactome screening (Figure 1A) we dissected the MyD88-interacting
complexes assembled in RAW cells under different inflammatory states including (1) no
stimulation (N), (2) challenging with a single high LPS dose (LPS-responsive, NL), (3)
priming with a low LPS dose (LPS-tolerant, T), and (4) challenging T cells with a high-dose
LPS (TL). Compared to NL cells, T or TL cells showed ET-specific phenotype of
immunosuppression and resistance to apoptosis (Figure S1A). Through phenotypic
interactome analysis (Figure 1A), we found that MyD88 interacts with different sets of
proteins in NL vs TL macrophages (detailed proteomic data will be reported elsewhere):
together with many negative immune regulators(Liew et al., 2005) including a negative TLR
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regulator Flii (Wang et al., 2006), PP2Ac was found recruited into the MyD88 interactome
specifically in ET cells (Figure 1B and Figure S1B). Because approximately 20% of the
components in TL-specific MyD88 interactome contain the domains interacting with PP2Ac
(Figure S1C) that is generally considered as a suppressor of pro-inflammatory kinases
(Junttila et al., 2008), this inflammation-phenotypic proteomic finding suggested that PP2Ac
plays a central, MyD88-dependent, immunosuppressive role during ET.
Given neither expression nor stability of PP2Ac was affected by LPS-induced inflammation
(Figure S2A), we compared the PP2Ac activity in RAW cells under different inflammatory
conditions. Compared to naïve (N) cells, while its activity was little changed under NL,
PP2Ac was highly activated with a prolonged stimulation and was sustained under TL
(Figure 1C), indicating the activity-based, inflammation-phenotypic function of PP2Ac. To
clarify the MyD88-dependence of PP2Ac activation, we measured PP2Ac activity in paired
wild-type (WT) and MyD88-depleted (MyD88−/−) (Figure S2B) BMDMs under different
inflammatory states induced by a variety of TLR agonists. Similar to RAWs, PP2Ac activity
showed a 2-fold increase in TL WT BMDMs but less than 10% changes in MyD88−/−
BMDMs under N, NL, TL (Figure 1D). The TLR9 agonist CpG, which triggers only
MyD88-dependent pathways, induced a greater increase in PP2Ac activity in TL WT
BMDMs than that induced by LPS which activates both MyD88-dependent and -
independent pathways (Figure 1E), while no differences in PP2Ac activity were observed
between WT and MyD88−/− BMDMs when the TLR3 agonist Poly (I:C) stimulated only
MyD88-independent pathways (Figure 1F). These agonist-specific effects indicated the
MyD88-dependent activation of PP2Ac in chronic-inflamed cells. Second, to clarify how
PP2Ac activity is regulated in tolerant macrophages, we respectively used either LPS-
conditioned medium, i.e., that separated from the LPS-pretreated RAWs, or TNFα or
ionizing radiation (IR) to trigger inflammation in BMDMs. Under chronic exposure all non-
TLR stimuli caused a similar degree of tolerance-specific activation of PP2Ac in both WT
and MyD88−/− BMDMs (Figure 1G). In a coordinate manner, unlike its LPS-inducible
nature in WT but not in MyD88−/− BMDMs (Figure 1H, left), phospho-p65 triggered by
non-TLR stimuli showed similar time-dependent induction in both types of BMDMs (Figure
1H, right), indicating that stimuliinduced, secondary, NFκB-regulated production of
inflammatory cytokines such as TNFα causes tolerance-specific PP2Ac activation. Because
TNFα is a T-class gene and its release is MyD88-promoted (Figure S2B), this secondary
effect on PP2Ac activation was therefore more pronounced in the WT BMDMs directly
stimulated by the TLR agonists that trigger MyD88- dependent pathways for producing
these T-class cytokines. Therefore, only during the chronic inflammation mediated by
TLR2/4/9, the sustained PP2Ac activation is MyD88-dependent.
Constitutively Active PP2Ac Regulates Immunosuppression During ET
To determine the correlation of persistently or constitutively activated PP2Ac with
immunosuppression, we measured cytokine release from stable RAW lines expressing either
shRNA for knocking down PP2Ac (PP2Ac KD) or shRNA for GFP (WT control) (Figure
2A and S2C). Under NL, most cytokines showed LPS-inducible releases in both PP2Ac KD
and WT RAWs (Figure 2B). In contrast, compared to the LPS-tolerized WT RAWs showing
reduced production of T-class cytokines, the LPS-primed PP2Ac KD cells were hyper-
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responsive to highdose LPS stimulation and released greater amounts of cytokines. Further,
we determined the effect of constitutively active PP2Ac on the expression of 84 mouse
genes encoding inflammatory factors, most known to be regulated by NFκB (Figure S2D).
Compared with their levels in WT RAWs, 34 out of 84 genes showed more than 30%
increases (Table S1), some of which were validated by qPCR (Figure 2B). Also, T-class
genes (IL6 or IL10) had dramatically enhanced expression in the PP2Ac KD cells even
under TL, reversing their suppressed expression in TL WT cells. In contrast, under NL or
TL PP2Ac knockdown had little effect on the LPS-inducible trend of Fpr1 (Figure 2B), a
non-tolerizeable gene (Foster et al., 2007), suggesting that constitutivelyactive PP2Ac is
involved specifically in T-class gene regulation under ET.
Further, to determine whether the constitutively active form of PP2Ac directly contributes to
ET-acquiring, we transfected constructs expressing either WT or a dominant-negative (DN)
mutant of PP2Ac(Chang et al., 2011) into the PP2Ac KD RAWs. Under TL, while
expression of WT PP2Ac restored the tolerance with reduced IL6, the PP2Ac DN mutant
with similar expression failed to suppress this T-class gene (Figure 2C), indicating that
constitutively active PP2Ac participates in the gene-specific control of chronic inflammation
by selectively suppressing T-class genes.
Constitutively Active PP2Ac Promotes the MyD88-dependent Survival of ET Cells Through
Broadly Targeting Pro-inflammatory Kinases and Pro-apoptotic Factors
To identify those PP2Ac-target pathways through which ET is regulated by constitutively
active PP2Ac, we profiled the phosphoproteomic changes in PP2Ac KD versus WT RAWs
under TL (Figure S3A). Some of PP2Ac-target sites (Figure S3B) that were identified based
on their phosphorylation increases in TL PP2Ac-depleted cells were in the components of
TL-specific MyD88 interactome (Figure S1B), including Rps6 (a substrate of p70S6K),
Rap1 (a MAPK component), Akt1, and a mTORC1/C2 component Raptor, revealing that
through sitespecific dephosphorylation constitutively active PP2Ac represses the pro-
inflammatory/-apoptotic activity of the PI3K-mTOR-p70S6K-Akt pathway. In addition, we
found that constitutively active PP2Ac targeted AP1/c-Jun, the mediator of stimuli-induced
apoptosis (Li et al., 2004) (Figure S3C): under TL, in contrast to its decreased abundance in
WT RAWs, phosphorylation of c-Jun Ser63 was found significantly increased when PP2Ac
was depleted (Figure 2D). Thus, similarly to the anti-apoptotic nature of PP2A (Kong et al.,
2004), PP2Ac, when constitutively activated, negatively regulates the pro-apoptotic activity
of c-Jun by directly dephosphorylating its pro-apoptotic pSer63.
We next determined how PP2Ac knockdown affects the ET-characteristic resistance to
apoptosis. First, we evaluated cell survival/proliferation in PP2Ac KD RAWs under N, NL,
TL in the presence of cycloheximide (CHX) that can amplify LPS-induced apoptosis
(Suzuki et al., 2004). Compared with the ET-specific increase of the surviving WT cells,
PP2Ac knockdown led to reduced colony formation, indicating the increasing apoptotic/
dead cells even under TL (Figure 2E). Similarly, in flow cytometry analysis, consistent with
what was shown for cytokine release (Figure 2B), PP2Ac KD RAWs showed some degree
of LPS-inducible apoptosis/cell death even in non-stimulated cells (Figure 2F), indicating
the cell sensitization due to PP2Ac depletion. The NL WT RAWs showed LPS-inducible
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apoptosis, whereas this induction was suppressed under TL. In contrast, a dramatically
increased susceptibility to apoptosis was observed even for T or TL PP2Ac KD cells. The
consistent results from both assays (Figure 2E and 2F) indicated that PP2Ac depletion
reduces the resistance of ET macrophages to apoptosis.
Further, because MyD88 promotes tumor growth by either modulating particular kinase
pathways(Lee et al., 2010) or inhibiting apoptosis(Rakoff-Nahoum and Medzhitov, 2007),
we next examined whether the PP2Ac effect on apoptotic propensity is MyD88-dependent.
Because PP2Ac is highly abundant and robust, and non-dividing BMDMs have extremely
low transfection efficiency and shRNA stability, very low percentages of endogenous
PP2Ac KD could be achieved in BMDMs (data not shown). Given that the phosphatase
inhibitor okadaic acid (OA) at concentrations <50 nM showed greater specificity in
inhibiting the activity of PP2Ac to that of PP2Ac DN (Chang et al., 2011), we used 20 nM
OA to mimic PP2Ac KD in the experiments involving BMDMs. Accordingly, we observed
similar increases of c-Jun pSer63 in either PP2Ac KD RAW or OA-treated BMDMs, both
under TL (Figure 2D and Figure S3C). Additionally, under T or TL, both WT and PP2Ac
KD RAWs pre-treated with 20 nM OA showed similar changes in the populations of
apoptotic/death cells (Figure 2F, middle versus bottom row). All these similarities in OA
treatment and shRNA-mediated PP2Ac KD on promoting apoptosis indicated the specificity
of 20 nM OA in inhibiting chronic-active PP2Ac.
We therefore used 20nM OA to investigate the MyD88 dependence of the PP2Ac effect in
primary WT vs MyD88−/− BMDMs. Accordingly, similar to WT RAWs, more WT BMDMs
underwent apoptosis/death under NL than those under TL (Figure S3D). Conversely,
viability of MyD88−/− BMDMs was unaffected by either NL or TL. Further, OA-mediated
PP2Ac inhibition triggered more apoptosis/death of TL WT but not MyD88−/− BMDMs.
Further, compared to their untreated counterparts, the OA-treated WT BMDMs under TL
showed features typical of mitochondrial-mediated apoptosis, including greater cleavage of
caspase-3 and PARP, and higher expression of the pro-apoptotic proteins Bak and Bax
(Figure 2G). In contrast, such an OA-initiated apoptosis in TL cells was abolished in
MyD88−/− BMDMs. Because c-Jun pSer63 is upstream of caspase-3 activation during
apoptosis(Li et al., 2004), thus, analysis of multiple, interconnected pathway-specific
apoptotic markers indicated that constitutively active PP2Ac promotes cell survival in a
MyD88-dependent manner.
Constitutively Active PP2Ac Dissociates the Signal-promoting TLR4-MyD88 Complex
Through Dephosphorylating key Serines in the Toll/IL-1 Receptor (TIR) Domain of MyD88
We next investigated the role of TL-specific PP2Ac-MyD88 interaction (Figure 3A, left) in
acquiring ET. First, we found that MyD88 binds to the WT PP2Ac more tightly than to the
PP2Ac DN under TL (Figure 3A, right), indicating that MyD88 interacts only with
constitutively active PP2Ac. Further, to identify exactly where constitutively active PP2Ac
targets MyD88, we employed an AACT-based quantitative proteomics approach where
tagged MyD88 expressed in HEK TLR4 stable cells was immunoprecipitated for MS
analysis because no phosphorylation on endogenous MyD88 was detected in the
phosphoproteomic analysis above. Meanwhile, we used 20nM OA to highlight PP2Ac-target
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phospho-sites on MyD88. In MyD88 immunoprecipitates from differentially stimulated
TLR4 stable cells, with or without 20nM OA treatment, we identified novel phosphorylation
sites at Ser242/244 (Figure 3B), and also found that these residues exhibited an LPS-
inducible increase in phosphorylation, more so in NL than in TL cells (Figure S4A and
S4B). Further, phosphorylation of these sites was increased approximately 30% in the OA-
treated TL cells (Figure 3C) compared to NL cells in which OA had little effect, suggesting
that constitutively active PP2Ac targets these phosphoserines for dephosphorylation. Thus,
we generated single (S242A and S244A) and double (S242A-S244A) non-phosphorylatable
mutants of MyD88, and found that constitutively active PP2Ac associated more strongly
with WT MyD88 than with any non-phosphorylatable mutant (Figure 3D), thus validating
these PP2Ac-recognizing sites in TL cells. Because these serines reside in the TLR4-
interacting MyD88 TIR domain that is critical for initiating pro-inflammatory signaling
(Wang et al., 2006) we reasoned that these LPS-inducible, PP2Ac-target phosphorylations
are essential for stability of the signal-promoting MyD88-TLR4 complex. Thus, we
examined the LPS-induced, time-dependent TLR4-MyD88 association, which reached its
highest strength at 15 min following LPS stimulation before returning to the basal level 24hr
after stimulation (Figure 3E, Left). We then generated an anti-phospho-Ser242 antibody
(Figure S4C) to assay the timedependent level of this pro-inflammatory MyD88
phosphorylation (pSer242) that also reached the highest level at 15min and was reduced
with prolonged LPS stimulation (Figure 3E, Middle). We then compared binding of TLR4 to
WT MyD88 versus each mutant in co-transfected cells stimulated by LPS for 15 min.
Compared with WT MyD88, binding of each non-phosphorylatable mutant to TLR4 was not
only weaker but also not LPS-inducible (Figure 3E, Right). These results together revealed
that site-specific phosphorylation(s) in the MyD88 TIR are directly involved in the pro-
inflammatory TLR4-MyD88 interaction, also demonstrating the physiological accuracy of
our quantitative proteomic method for identification of these sites first with 20nM OA
treatment.
To determine the impact of the PP2Ac-mediated MyD88 dephosphorylation on T-class gene
regulation, we transfected WT and the non-phosphorylatable MyD88 mutants into
MyD88−/− BMDMs. Coincident with the weakened binding of MyD88 mutants to TLR4
(Figure 3E), following a high-dose Pam3CSK4 stimulation (MyD88-dependent TLR2
agonist), a 50% reduction in TNFα was observed for the mutant-expressing cells compared
to cells expressing WT MyD88 (Figure 3F). Clearly, disruption of the phosphorylation-
dependent TLR4-MyD88 complex by constitutively active PP2Ac directly contributes to
suppression of T-class genes.
Constitutively Active PP2Ac Co-localizes with MyD88 in the Nuclei of Tolerant
Macrophages
Given that constitutively active PP2Ac facilitates the departure of MyD88 from the TLR4
complex through site-specific dephosphorylation that often regulates protein
translocation(Deribe et al.), we then determined the ET-specific distribution of MyD88 and
PP2Ac. Compared to their subcellular distributions in pro-apoptotic NL cells, both MyD88
and PP2Ac showed coincidently increased presence in the nuclei of the TL, pro-survival WT
BMDMs (Figure 3G), in line with previous report that MyD88 was preferentially in nuclei
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of non-apoptotic cells(Jaunin et al., 1998). Further, immunoblotting revealed that more
MyD88 and PP2Ac were retained in the nuclei of LPS-tolerant WT BMDMs than in naïve
cells (Figure 3H). In contrast, in the PP2Ac KD cells under TL, MyD88 failed to accumulate
in nuclei. Similarly, OA-mediated PP2Ac inhibition reversed survival-characteristic
retention of MyD88. Immunofluoresence staining further indicated that more PP2Ac and
MyD88 co-localized in nuclei of TL WT macrophages than those in non-stimulated cells
(Figure 3I, yellow spots in the nuclei area), all indicating that chronic-active PP2Ac
promotes survival-specific translocation of MyD88 to ET nuclei through MyD88
dephosphorylation.
Constitutively-Active PP2Ac Plays a MyD88-dependent Role in Establishing the Gene-
specific Chromatin Modifications Responsible for Acquiring ET
We next explored the impact of the nuclear MyD88/PP2Ac accumulation on T-class gene
regulation. First, along with the increasing PP2Ac in ET nuclei, the LPS-inducible increase
of phospho-p65 was significantly suppressed in TL WT cells (Figure 3G, left lanes 2–4).
Either PP2Ac KD or OA treatment dramatically reversed TL-specific suppression of p-p65,
indicating chronic-active PP2Ac specifically dephosphorylates p-p65. Additionally,
although p-p65 was suppressed, p65 was even higher in TL nuclei, indicating abnormal
nuclear retention of non-phosphorylated p65 under ET. We then clarified the impact of
PP2Ac-mediated p65 dephosphorylation on NFκB-regulated T-class genes and its MyD88-
dependence: in contrast to the MyD88-dependent suppression of IL6/IL10 in the TL WT
BMDMs, OA inhibition of PP2Ac activity reactivated their releases under LPS stimulation,
also more so with Pam3CSK4 treatment for MyD88-dependent pathways (Figure 4A), all
suggesting that, in a MyD88-dependent manner, chronic-active PP2Ac renders NFκB-
dependent genes unresponsive by dephosphorylating nuclear p65 in ET macrophages.
Additionally, our phosphoproteomic findings of PP2Ac-target chromatin assembly/
remodeling factors such as SWI/SNF (Figure S3B) implied that nuclear translocated,
constitutively active PP2Ac directly participate in the gene-specific chromatin
modifications. First, because histone H3 Ser10 phosphorylation (H3pS10) reflects the
accessibility of NFκB to T-class genes and mediates NFκB-dependent transactivation of
these genes (Saccani et al., 2002), we determined whether constitutively active PP2Ac
affects this pro-inflammatory epigenetic marker. Compared with its NL-enhanced but TL-
suppressed nature in irritated WT cells, H3pS10 remained high in PP2Ac KD cells under NL
or TL (Figure 4B), indicating that constitutively active PP2Ac specifically targets H3pS10.
Further, the LPS-inducible H3pS10 under NL was fully suppressed in TL WT BMDMs that
was reversed by OA pre-treatment, whereas no such OA effect was observed for NL cells
(Figure 4C). As well, no detectable change due to OA treatment was observed in MyD88−/−
BMDMs under TL, all indicating that in a MyD88-dependent manner, constitutively active
PP2Ac dephosphorylates H3pS10 to selectively restrict accessibility of NFκB to T-class
gene promoters.
We then determined the link of the PP2Ac-coordinated MyD88 signaling to two major
characteristics of the gene-specific regulation, histone deacetylation and inhibition of
chromatin remodeling, at T-class gene promoters under TL (Foster et al., 2007). First, the
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reversed suppression of IL-6 and IL-10 in the TL WT BMDMs pretreated with a HDAC
inhibitor (SAHA) was not observed in the TL MyD88−/− cells (Figure 4D), indicating that
histone deacetylation is MyD88-dependent. Second, levels of both p-Ser10 and acetyl-lysine
9 on H3 showed similar OA-triggered MyD88-dependent changes (Figure 4C), indicating
that in the MyD88 interactome chronic-active PP2Ac negatively regulates histone
acetylation in a phosphorylation-dependent manner.
In combination, our findings of MyD88-dependent, PP2Ac-mediated p65 dephosphorylation
and PP2Ac-target HDAC1 and chromatin remodeling complexes (Figure S3B) suggested
that, in a phosphorylation-dependent manner, chronic-active PP2Ac directly regulates
TLR4-induced recruitment of chromatin remodeling complexes to T-class gene promoters, a
process is inhibited in tolerant macrophages. Thus, we examined the effect of PP2Ac KD on
recruitment of an ATP-dependent chromatin remodeling complex, Brg1, to T-class
promoters, which was found suppressed under TL(Foster et al., 2007). As revealed by ChIP
experiments, either PP2Ac KD or OA-mediated PP2Ac inhibition similarly reversed the ET-
specific suppression of Brg1 recruitment to the IL6 and Lipg promoters (Figure 4E). Further,
this pro-inflammatory recruitment was heavily suppressed in the TL WT BMDMs but
suppressed to a much lower degree in the TL MyD88−/− BMDMs (Figure 4F). By contrast,
while OA had little effect on Brg1 in the NL WT BMDMs, the TL WT BMDMs pre-treated
with OA showed greater Brg1 recruitment. However, this OA-initiated Brg1 recruitment
was not observed in the TL MyD88−/− BMDMs. These results indicated that chronic-active
PP2Ac co-translocated with MyD88 negatively regulates the chromatin modification/
remodeling required for T-class gene transactivation.
DISCUSSION
Here we have revealed a novel mechanism by which TLR4-induced, constitutively active
PP2Ac broadly intersects with multiple, MyD88-dependent, interconnected signaling
pathways and epigenetic regulation programs at both signal-specific and gene-specific levels
for controlling inflammation as macrophages acquire ET.
At the signaling level, because PP2Ac-targeted p-Ser242/Ser244 locate in the highly
accessible area close to the conserved lymphoma-associated, survival-promoting
Leu-265(Ngo et al., 2011), we rationalized that under the TL condition with a lymphoma-
mimicking chronic inflammatory environment, PP2Ac-mediated dephosphorylation of these
residues could generate charge changes in the MyD88 TIR domain (Ohnishi et al., 2009)
(Figure 4G), similarly leading to a weakened MyD88-TLR4 association and impaired pro-
inflammatory and proapoptotic programs with reduced sensitivity to apoptotic stimuli.
Consequently the dissociating MyD88 from TLR4 complex was translocated along with
constitutively active PP2Ac into the nuclei of tolerant macrophages indicative of increased
cell survival (Figure 4H). At the chromatin level chronic-active PP2Ac initiated the removal
of phosphorylation-dependent acetylation, established T gene-specific chromatin
modification, and suppressed the phosphorylation-dependent, Brg-mediated nucleosome
remodeling for silencing of T-class genes (Figure 4H).
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From the perspective of a dynamic system, we have established a direct link between gene-
specific and signal-specific regulation coordinately for the control of chronic inflammation,
elucidating how the differential regulation of pro-inflammatory versus antimicrobial genes
at the chromatin level is achieved. Of clinical relevance, the specific protein interactions in
the tolerance-specific MyD88 interactome coordinated by constitutively active PP2Ac that
we have dissected may be targeted to unleash or attenuate cellular inflammatory responses.
This knowledge is critical to better understand how MyD88 signaling produces diverse
pathologic outcomes, including tissue repair and carcinogenesis, under different
inflammatory conditions.
EXPERIMENTAL PROCEDURES
Proteomic Identification of TL-specific MyD88 Interactors
The details about sample preparation, nano-LC-MS/MS analysis, AACT-based quantitative
proteomic identifications of NL-or TL-specific MyD88-interacting partners are given by
EXTENDED EXPERIMENTAL PROCEDURES.
BMDM Stimulation and OA or SAHA Treatment
LPS stimulations of differentiated BMDMs were similar as to RAWs. In Pam3CSK4
stimulations the priming dose was at 50ng/ml and a high dose was 500ng/ml. SAHA was
introduced into media 24 hrs before stimulation and 20nM OA was added along with the
stimuli.
PP2A Activity Assay
PP2Ac was immunoprecipitated (IP) using anti-PP2Ac antibody with protein A agarose
from 0.5–1.0 mg of each lysate of differentially stimulated cells. The phosphatase activity of
IP PP2Ac was measured by Phosphatase Assay Kit (Millipore) and normalized based on the
amount of PP2Ac in the IP products.
Generation of the RAW stable lines with either shRNA-GFP or –PP2Ac
The lentiviral plasmids pLKO.1 expressing the shRNA-PP2Ac targeting sequences
CCAGATACAAATTACCTGTT and CGACGAGTGTTTAAGGAAATA were purchased
from Thermo Scientific. To produce virus, pLKO.1-shRNA plasmids were co-transfected
into 293T cells with ViraPower Mix (Invitrogen) by jetPRIME™ in vitro DNA & siRNA
transfection reagent (Polyplus). Pseudo-virus in supernatants was collected after 48 hrs
following transfection and used to transduce RAWs by spinoculation. 48 hrs after
transfection, 8µg/ml puromycin was added to select puromycin-resistant clones. Stable
clones were maintained in the media containing 4µg/ml puromycin.
Identification of LPS-Inducible, PP2Ac-target Phosphorylations at MyD88
Due to the low abundance of endogenous MyD88 in RAW cells few phosphorylation sites
could be identified/quantified for their LPS-inducible changes. Therefore, quantitative
proteomic identification of novel phosphorylation sites on MyD88 and the analysis of LPS
or OA effects on these sites were conducted on the AACT-tagged HEK 293 cells stably
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expressing TLR4-MD2- CD14. The details are given by EXTENDED EXPERIMENTAL
PROCEDURES.
Retrovirus Infection and Cytokine Assay
Each cDNA of wild-type MyD88 or a MyD88 mutant was inserted into the MIG vector
(Wang et al., 2010). Viral particles were generated in 293T cells and infected bone marrow
cells 3 times. 5 days after infection, matured BMDM cells were processed for LPS
stimulation as described above.
Analysis of LPS-induced Binding between TLR4 and Wild-type or Mutant Myd88
HEK-TLR4 stable cells were co-transfected with both YFP-TLR4 and HA-WT or a mutant
MyD88 by using jetPRIME (Polyplus). The cells were stimulated with 1µg/ml LPS for
indicated time and harvested. The cells were lysed in the buffer (50mM Tris, pH8.0, 150mM
NaCl, 1mM EDTA, 1% Triton, protease inhibitor and phosphatase inhibitors (Sigma). 1mg
lysate was incubated with the anti-GFP IgG coupled on Protein A magnetic beads for co-IP
and immunoblotting.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This work is supported by NIH grants to X.C. (NIH R01AI064806 and NIH 1U24CA160035), L.P. (NIH
1R01HL092544 and AHA 10GRNT3870017). We thank Dr. Howard Fried for editing the manuscript, Dr.
Hengming Ke for drawing the structure shown by Fig. 4G, and Dr. S. Zhang for technical assistance. L.X., C.L.,
L.W., J.Y., performed major biological/immunological experiments; H.G. and Y.Y performed quantitative
proteomics experiments; Z.Y. measured PP2Ac activity in radiation-treated BMDMs; R.D. analyzed mass spec data
and network analysis; D.T. and J.T. assisted in generating PP2Ac knock-down Raw264.7 cells; Y.W. provided
advice for BMDM transfection and helpful discussion. S.H. and L.P. assisted in flow cytometry analysis; X.C.
conceived the project, designed the experiments, analyzed the results, and wrote the manuscript.
Abbreviations used
MyD88 Myeloid differentiation primary response gene (88)
TLR Toll-like receptors
ET endotoxin tolerance
PP2Ac protein phosphatase catalytic subunit a
AACT amino acid-coded mass tagging
interactome protein-protein interaction network
KD knockdown
REFERENCES
Chang HY, Jennings PC, Stewart J, Verrills NM, Jones KT. Essential Role of Protein Phosphatase 2A
in Metaphase II Arrest and Activation of Mouse Eggs Shown by Okadaic Acid, Dominant Negative
Xie et al. Page 10






















Protein Phosphatase 2A, and FTY720. The Journal of biological chemistry. 2011; 286:14705–
14712. [PubMed: 21383018]
Chen X, Smith LM, Bradbury EM. Site-specific mass tagging with stable isotopes in proteins for
accurate and efficient protein identification. Analytical chemistry. 2000; 72:1134–1143. [PubMed:
10740850]
Dai P, Jeong SY, Yu Y, Leng T, Wu W, Xie L, Chen X. Modulation of TLR signaling by multiple
MyD88-interacting partners including leucine-rich repeat Fli-I-interacting proteins. J Immunol.
2009; 182:3450–3460. [PubMed: 19265123]
Deribe YL, Pawson T, Dikic I. Post-translational modifications in signal integration. Nature structural
& molecular biology. 17:666–672.
Drexler SK, Foxwell BM. The role of toll-like receptors in chronic inflammation. The international
journal of biochemistry & cell biology. 42:506–518. [PubMed: 19837184]
Foster SL, Hargreaves DC, Medzhitov R. Gene-specific control of inflammation by TLR-induced
chromatin modifications. Nature. 2007; 447:972–978. [PubMed: 17538624]
Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H. TLR signaling by tumor and immune cells: a
double-edged sword. Oncogene. 2008; 27:218–224. [PubMed: 18176603]
Jaunin F, Burns K, Tschopp J, Martin TE, Fakan S. Ultrastructural distribution of the death-domain-
containing MyD88 protein in HeLa cells. Experimental cell research. 1998; 243:67–75. [PubMed:
9716450]
Junttila MR, Li SP, Westermarck J. Phosphatase-mediated crosstalk between MAPK signaling
pathways in the regulation of cell survival. Faseb J. 2008; 22:954–965. [PubMed: 18039929]
Kong, M.; Fox, CJ.; Mu, J.; Solt, L.; Xu, A.; Cinalli, RM.; Birnbaum, MJ.; Lindsten, T.; Thompson,
CB. Science. Vol. 306. New York, NY: 2004. The PP2A–associated protein alpha4 is an essential
inhibitor of apoptosis; p. 695-698.
Lee SH, Hu LL, Gonzalez-Navajas J, Seo GS, Shen C, Brick J, Herdman S, Varki N, Corr M, Lee J, et
al. ERK activation drives intestinal tumorigenesis in Apc(min/+) mice. Nature medicine. 2010;
16:665–670.
Li L, Feng Z, Porter AG. JNK-dependent phosphorylation of c-Jun on serine 63 mediates nitric oxide-
induced apoptosis of neuroblastoma cells. The Journal of biological chemistry. 2004; 279:4058–
4065. [PubMed: 14617628]
Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of toll-like receptormediated immune
responses. Nature reviews. 2005; 5:446–458.
Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao
H, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011; 470:115–
119. [PubMed: 21179087]
Ohnishi H, Tochio H, Kato Z, Orii KE, Li A, Kimura T, Hiroaki H, Kondo N, Shirakawa M. Structural
basis for the multiple interactions of the MyD88 TIR domain in TLR4 signaling. Proceedings of
the National Academy of Sciences of the United States of America. 2009; 106:10260–10265.
[PubMed: 19506249]
Rakoff-Nahoum, S.; Medzhitov, R. Science. Vol. 317. New York, NY: 2007. Regulation of
spontaneous intestinal tumorigenesis through the adaptor protein MyD88; p. 124-127.
Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer. 2009; 9:57–63.
[PubMed: 19052556]
Saccani S, Pantano S, Natoli G. p38-Dependent marking of inflammatory genes for increased NF-
kappa B recruitment. Nature immunology. 2002; 3:69–75. [PubMed: 11743587]
Suzuki T, Kobayashi M, Isatsu K, Nishihara T, Aiuchi T, Nakaya K, Hasegawa K. Mechanisms
involved in apoptosis of human macrophages induced by lipopolysaccharide from Actinobacillus
actinomycetemcomitans in the presence of cycloheximide. Infection and immunity. 2004;
72:1856–1865. [PubMed: 15039304]
Wang T, Chuang TH, Ronni T, Gu S, Du YC, Cai H, Sun HQ, Yin HL, Chen X. Flightless I homolog
negatively modulates the TLR pathway. J Immunol. 2006; 176:1355–1362. [PubMed: 16424162]
Wang YQ, Souabni A, Flavell RA, Wan YY. An Intrinsic Mechanism Predisposes Foxp3-Expressing
Regulatory T Cells to Th2 Conversion In Vivo. Journal of Immunology. 2010; 185:5983–5992.
Xie et al. Page 11























• PP2Ac is chronically activated that targets MyD88 in LPS-tolerized
macrophages
• Chronic-active PP2Ac shifts a pro-inflammatory MyD88 to its pro-survival
mode
• Chronic-active PP2Ac reprograms gene-specific chromatin modification
landscape
• Chronic-active PP2Ac broadly defines ET at both signaling and epigenetic
levels
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Figure 1. PP2Ac Enhances its Association with MyD88 and Shows a MyD88-dependent
Activation in ET Macrophages
(A) Experimental design of the AACT-based quantitative proteomics for phenotypic
compositional screening of the MyD88 interactomes under N, NL, TL. (B) Mass spectra of
the AACT-containing peptides of MyD88 and indicated TL-specific MyD88 interactors.
Shown for each protein is one spectrum representative of at least 2 peptides sequenced by
MS/MS. The PP2Ac activity was measured by phosphatase assay in RAWs (C), in WT and
MyD88−/− BMDMs (D) under N, or NL, or T, or TL, (E) stimulated by CpG, (F) by Poly
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(I:C), (G) by non-TLR stimuli including LPS-conditioned medium, TNFα, and IR, (H)
agonist/cytokine-induced, time-dependent changes of PP2Ac activity and p-p65. Each bar
represents the mean ±SD of triplicates (same in Figures below).
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Figure 2. Chronic-active PP2Ac Promotes Immunosuppression and Cell Survival
(A) PP2Ac abundance in the WCL of WT PP2Ac (GFP) or PP2Ac KD RAWs. (B) Releases
of selected cytokines/chemokines were measured by qPCR for WT or PP2Ac KD cells
under different inflammation conditions. The stimulated cells were collected at 1–2 hrs after
high-dose stimulation. (C) RT PCR was used to monitor the IL6 releases from the PP2Ac
KD RAWs transfected with WT or L199P DN PP2Ac under TL (normalized by PP2Ac
mRNA). (D) MS/MS sequencing spectrum of the p-Ser63 c-Jun peptide and MS of its
quantitative changes in paired WT versus PP2Ac KD RAWs under N, NL, TL, validated by
Xie et al. Page 15






















immunoblotting (Inserted view). (E) Comparative colony counts on paired WT versus
PP2Ac KD RAWs under N, NL, TL. Cells were co-stimulated by 1 µg/ml LPS with 1 µg/ml
CHX for 12 hrs (NL/CHX), or tolerized before CHX treatment and a high-dose LPS
challenge (TL/CHX). P value as indicated. (F) Flow analysis of cell viability of the same set
of (E) RAWs. The apoptotic/death cells were gated in Q3/Q2. (G) Immunoblot analysis of
caspase-9, caspase-3, PARP (a substrate of caspase-3), and expression of pro-apoptotic Bak
and Bax in the TL WT (left panel) or MyD88−/− (right panel) BMDMs. Immunoblot
intensities were quantified by a densitometry.
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Figure 3. Chronic-active PP2Ac Dephosphorylates MyD88 for Dissociating Proinflammatory
TLR4-MyD88 Complex and Promoting Its Co-translocation with MyD88
(A) (Left) Immunoblot analysis of the immunoprecipitates from the TLR4 stable 293 cells
cotransfected with MYC-tagged PP2Ac and HA-tagged MyD88 fused with GyrB (MyD88-
GyrB) under N, NL, or TL. (Right) HA-MyD88-GyrB was co-transfected with either MYC
WT or DN PP2Ac construct respectively into the TLR4 stable cells that were induced to TL.
(B) MS/MS spectrum of the phosphorylated S242 or S244 MyD88 peptide. (C) Effects of
PP2Ac inhibition on the LPS-inducible S242/S244 phosphorylation of the MyD88
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immunoprecipitated from the TLR4 stable cells under NL or TL. (Right) MS spectra of this
peptide with or without p-S242/244. (Left) the fold-change of phosphorylation caused by
OA (y-axis) under TL calculated by Figure S3B. (D) MYC-PP2Ac was co-transfected with
the construct of HA-WT or a nonphosphorylatable mutant MyD88 into the TLR4 stable cells
before TL induction for immunoblot analysis. (Left) LPS-induced, time-dependent bindings
between YFP-tagged TLR4 and WT MyD88. (Middle) the level of pSer242 in LPS-induced,
time-dependent TLR4-MyD88 complexes blotted by anti-pSer242 antibody. (Right)
Comparative bindings of TLR4 to either WT or nonphosphorylatable mutants of MyD88 in
the TLR4 stable cells following 15 min LPS stimulation. (E) (Top) MyD88−/− BMDMs were
infected by retrovirus-packaged each of the constructs containing WT, S242A, S244A, and
S34A MyD88 and then stimulated by Pam3CSK4 for 1 hr. TNFα mRNA was measured by
RT-PCR for each MyD88-expressing BMDMs without or with stimulation. “EV” refers
empty retrovirus. “NV” is the non-infected MyD88−/− control. (Bottom) MyD88 expression
in non- or transfected MyD88−/− BMDMs. (F) Cytoplasmic and nuclear distributions of
MyD88, PP2Ac, and p65 in BMDMs under N, NL, T, TL; Lmnb1 as a nuclear marker. (G)
Immunoblot analysis of the nuclear fraction of PP2Ac KD or WT RAWs. (H) Confocal
microscopy of the subcellular co-localization of MyD88 and PP2Ac. The bar blot shows the
ratio of green density in nuclei vs the cytoplasm, ten spots with same square of area for each
compartment.
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Figure 4. Chronic-Active PP2Ac Directly Participates in TLR-induced, MyD88-dependent,
Gene-specific Chromatin Modifications
(A) A high (500ng/ml) or priming dose (50 ng/ml) of Pam3CSK4 was respectively used to
induce acute (NP) or chronic (TP) inflammation. RNA was harvested at 1 hr after
stimulation and analyzed by RT-qPCR and the data were normalized by GAPDH, p values
are as indicated. Immunoblot analysis of (B) pSer10H3 in WT or PP2Ac KD RAWs under
N, NL, T and TL. (C) LPS-induced changes of pSer10H3 or acetylated H3 in WT or
MyD88−/− BMDMs. (D) Cells were treated by 2 mM SAHA for 24 hrs prior to stimulation.
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Similar to (A), IL-6/IL-10 mRNAs were measured for those isolated from the WT or
MyD88−/− BMDMs with indicated treatment(s). (E) WT or PP2Ac KD RAWs with
indicated treatment(s) were fixed with DSG/formaldehyde 3 hrs after stimulation and
analyzed by ChIP (Brg1). qPCR was normalized to INPUT. (F) WT or MyD88−/− BMDMs
with indicated treatment(s) were analyzed by ChIP (Brg1). (G) Location of serine
phosphorylations in the MyD88 TIR domain. S242(m) and S244(m) are the mouse
counterparts (NP_034981) of human S255(h) and S257(h) (NP_002459), and (H) The
mechanistic model for the PP2Ac-integrated control of the inflammation.
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